Background: Sofosbuvir (SOF), an inhibitor of the Hepatitis C virus (HCV) NS5B polymerase, is a uridine nucleotide analog pro-drug. In cells, SOF is metabolized by host enzymes to GS-331007 (007) mono- (MP), di- (DP), and the pharmacologically active tri-phosphate (TP). There are limited data on the pharmacology of 007 TP in various cell types. We sought to characterize the pharmacology of SOF in peripheral blood mononuclear cells (PBMC).
Methods: PBMC were collected from HCV-infected individuals receiving SOF-based HCV treatment during routine clinic visits. HCV treatment duration was extracted from medical records and times of prior doses were by patient self-report. 007 MP, DP, and TP concentrations were determined using a validated LC-MS/MS assay linear in the range of 50-50000 fmol/sample, then normalized to a concentration per 106 cells (fmol/M). Log transformed data were naïve pooled to calculate 007 MP, DP and TP half-lives (t1/2). Effects of clinical covariates on 007 phosphate concentrations were tested using unpaired t-tests for categorical covariates or Pearson correlation for continuous covariates.
Results: PBMC were obtained from 45 individuals (29 genotype 1, 28 male, 5 African-American, 31 cirrhotic, 22 decompensated) receiving SOF plus ribavirin (RBV, n=27), simeprevir (SIM, n=7), or both (n=11) for a median (range) of 29 (19, 162) days of treatment and between 2.3 and 27 hours post-dose. All TP samples were quantifiable, while 2 MP and 16 DP were below the limit of assay detection. Median (range) concentrations were 220 (51.5, 846), 70.2 (25.8, 275), and 859 (54.5, 6756) fmol/M for PBMC 007 MP, DP, and TP, respectively. Estimates of t1/2 were 13.8 (MP) and 26.0 (TP) hours. MP (203 vs. 375 fmol/M; p=0.03) and TP (970 vs. 2280 fmol/M; p=0.01) were significantly higher in subjects taking SIM. 007 phosphate concentrations did not differ by race, sex, presence of cirrhosis or decompensation and were not significantly correlated with age, weight or creatinine clearance.
Conclusions: 007 phosphates are formed within PBMC, with the TP moiety representing the major anabolite. Higher MP than DP concentrations suggest that DP production may be a rate limiting step. 007 TP was predicted to have a long intracellular half-life in PBMC. SIM co-administration was associated with higher 007 MP and TP, possibly due P-glycoprotein inhibition by SIM. Additional well-controlled pharmacokinetic studies of intracellular SOF are needed, including an assessment of cell-specific pharmacology.